|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
|---|---|
| Information provided by: | National Institutes of Health Clinical Center (CC) |
| ClinicalTrials.gov Identifier: | NCT00001241 |
Purpose
In patients with Zollinger-Ellison Syndrome the level of gastric acid is elevated. This increased level of gastric acid is what causes the symptoms of the disease. Certain types of medication can control the secretion of gastric acid. In this study there are details on how drugs known as antihistamines (H2 receptor antagonists) can control the levels of gastric acid secretion.
The study describes; which patients are candidates for this research, what to do prior to initiating treatment, and the appropriate dose of antihistamine to be given.
Initial doses of the medication will be given intravenously (injected through a vein) and later doses will be administered orally (by mouth).
By following the procedure, researchers will be able to determine if there is a more effective route of drug administration, as well as the effectiveness of antihistamines in patients treated surgically for Zollinger-Ellison pancreatic tumors with mildly elevated gastric acid levels.
| Condition |
|---|
|
Zollinger Ellison Syndrome |
| Study Type: | Observational |
| Official Title: | Medical Therapy of Zollinger-Ellison Syndrome |
| Study Start Date: | January 1989 |
| Estimated Study Completion Date: | December 2007 |
This protocol describes the use of histamine H2-receptor antagonists to control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. It details which patients will be considered for treatment with these agents, the pretreatment procedures and the procedures to be followed in establishing the proper intravenous dose of histamine H2-receptor antagonist. It also details the procedure to be used to establish a safe and effective oral long-term maintenance dose of either cimetidine, ranitidine, nizatidine, or famotidine. By following these procedures it will be possible to evaluate the effectiveness of intravenous histamine H2 therapy if it is determined this is important for antisecretory control during periods when patients cannot take oral gastric antisecretory agents. It will also be possible to evaluate the effectiveness of histamine H2-receptor in patients with Zollinger-Ellison syndrome after successful gastrinoma resection who continue to have mild gastric hypersecretion.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Basal gastric acid secretion of greater than 15 mEq/hr (normal less than 10) or greater than 5 mEq/hr if they have had a previous gastric resection, a fasting plasma concentration of immunoreactive gastrin of greater than 100 pg/ml (normal less than 100), a positive secretin provocative tests or histological diagnosis of gastrinoma.
Contacts and Locations More Information
| Study ID Numbers: | 890015, 89-DK-0015 |
| Study First Received: | November 3, 1999 |
| Last Updated: | March 5, 2008 |
| ClinicalTrials.gov Identifier: | NCT00001241 History of Changes |
| Health Authority: | United States: Federal Government |
|
Gastric Acid Secretion Histamine H2-Receptor Antagonists |
|
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Gastrointestinal Diseases Pancreatic Neoplasms Physiological Effects of Drugs Paraneoplastic Endocrine Syndromes Pathologic Processes Stomach Diseases Neoplasms by Site Zollinger-Ellison Syndrome Syndrome Peptic Ulcer Endocrine Gland Neoplasms Digestive System Neoplasms Disease |
Neoplasms by Histologic Type Carcinoma, Islet Cell Histamine Agents Endocrine System Diseases Intestinal Diseases Pharmacologic Actions Histamine H2 Antagonists Carcinoma Neoplasms Digestive System Diseases Paraneoplastic Syndromes Gastrinoma Histamine Antagonists Gastrointestinal Neoplasms Pancreatic Diseases |
